Fundraising Fox

Clare Ozawa

Investor

Managing Director at Versant Ventures

San Diego, California

Writes $100K – $5M checks · typically $1.5M

About

Clare Ozawa combines a Stanford Ph.D. with experience as COO/CBO at Inception Sciences, leads San Diego–Bay Area investments and sits on boards of Capsida, Lycia, Gate Bioscience and 858 Therapeutics.

Invests in

BiotechHealthtechMedical Devices

Experience

  1. Versant VenturesManaging Directorcurrent2017 — present
  2. Inception SciencesChief Operating Officer, Chief Business Officer2011 — 2018
  3. Versant VenturesInvestment Professional2008 — 2010
  4. Versant EuroVenturesVP Business Development & Licensing2008 — 2010
  5. NovartisAssistant to CEO Pharma2006 — 2008
  6. McKinsey & CompanyEngagement Manager2002 — 2006

Education

  1. Stanford University School of MedicinePhD, Neurosciences
  2. Stanford UniversityB.S., Biological Sciences

Skills & more

Venture Capital18Biotechnology17Pharmaceuticals1Start-ups20Business Strategy11Corporate Development4Management Consulting5Medical Devices3Business Development8Oncology2Analytics3Lifesciences5
+6 moreHealthcareLife SciencesStrategic PlanningStrategyManagementPharmaceutical Industry

From Clare's professional profile.

Same school

Shared employers

Deals · 6

Lycia TherapeuticsBoard seat

via Versant Ventures · filed Jun 2026 · $75M raise

press ↗

858 Therapeutics, Inc.Board seat

via Versant Ventures · filed Jul 2024 · $50.4M raise

Presbyopia TherapiesBoard seat

via Versant Ventures · filed Mar 2023 · $83.5M raise

March Therapeutics, Inc.Board seat

via Versant Ventures · filed Sep 2022 · $30.3M raise

Jengu Therapeutics, Inc.Board seat

via Versant Ventures · filed Sep 2020 · $50M raise

Mistral TherapeuticsBoard seat

via Versant Ventures · filed Jun 2018 · $59.3M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Versant Ventures

Network5

Investors connected to Clare in public investor directories — a warm-intro map.